Julian Blagg

Company: NeoPhore

Job title: EVP Drug Discovery

Seminars:

NP1867: A Chemical Probe for Exploring the Role of DNA Mismatch Repair in Human Disease 11:30 am

• MMR-deficient (MMR-d) tumors are eligible for immune checkpoint therapy, irrespective of tumors type, providing substantial clinical benefit; however, not all MMR-d patients respond to CPI therapy and correlation of tumors mutational burden with clinical outcome is controversial • Small molecule NP1867 potently and selectively binds to the MutLa heterodimer component PMS2 enabling acute and…Read more

day: Day Two Track A